偶发性抗磷脂抗体 (aPL) 患者的血栓形成预防：一项荟萃分析和 2 项回顾性研究提供中等级证据表明，阿司匹林对该患者组中的抵抗血栓形成可能起保护作用。[49]Hereng T, Lambert M, Hachulla E, et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus. 2008;17:11-15.http://www.ncbi.nlm.nih.gov/pubmed/18089677?tool=bestpractice.com[50]Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:924-929.http://rheumatology.oxfordjournals.org/content/41/8/924.longhttp://www.ncbi.nlm.nih.gov/pubmed/12154210?tool=bestpractice.com[52]Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13:281-291.http://www.ncbi.nlm.nih.gov/pubmed/24189281?tool=bestpractice.com
系统评价或者受试者＞200名的随机对照临床试验（RCT）。
偶发性抗磷脂抗体 (aPL) 患者的血栓形成预防：一项荟萃分析和 2 项回顾性研究提供中等级证据表明，阿司匹林对该患者组中的抵抗血栓形成可能起保护作用。[49]Hereng T, Lambert M, Hachulla E, et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus. 2008;17:11-15.http://www.ncbi.nlm.nih.gov/pubmed/18089677?tool=bestpractice.com[50]Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:924-929.http://rheumatology.oxfordjournals.org/content/41/8/924.longhttp://www.ncbi.nlm.nih.gov/pubmed/12154210?tool=bestpractice.com[52]Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13:281-291.http://www.ncbi.nlm.nih.gov/pubmed/24189281?tool=bestpractice.com
有 VTE 病史患者的复发性血栓形成预防：2 项对比常规和高强度华法林疗法对静脉血栓栓塞患者疗效的随机临床试验提供质量差的证据表明，高强度疗法疗效并不优于常规治疗剂量的维生素 K 拮抗剂，而且可能与出血风险增加有关。[35]Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.http://www.nejm.org/doi/full/10.1056/NEJMoa035241#t=articlehttp://www.ncbi.nlm.nih.gov/pubmed/13679527?tool=bestpractice.com[36]Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-853.http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2005.01340.x/fullhttp://www.ncbi.nlm.nih.gov/pubmed/15869575?tool=bestpractice.com
系统评价或者受试者＞200名的随机对照临床试验（RCT）。
有 VTE 病史患者的复发性血栓形成预防：2 项对比常规和高强度华法林疗法对静脉血栓栓塞患者疗效的随机临床试验提供质量差的证据表明，高强度疗法疗效并不优于常规治疗剂量的维生素 K 拮抗剂，而且可能与出血风险增加有关。[35]Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.http://www.nejm.org/doi/full/10.1056/NEJMoa035241#t=articlehttp://www.ncbi.nlm.nih.gov/pubmed/13679527?tool=bestpractice.com[36]Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848-853.http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2005.01340.x/fullhttp://www.ncbi.nlm.nih.gov/pubmed/15869575?tool=bestpractice.com
偶发性 aPL 患者的血栓形成预防：一项大规模双盲、安慰剂对照的阿司匹林对比安慰剂试验提供低等级证据表明，两组间的血栓形成率没有区别。[51]Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382-2391.http://onlinelibrary.wiley.com/doi/10.1002/art.22663/fullhttp://www.ncbi.nlm.nih.gov/pubmed/17599766?tool=bestpractice.com
系统评价或者受试者＞200名的随机对照临床试验（RCT）。
偶发性 aPL 患者的血栓形成预防：一项大规模双盲、安慰剂对照的阿司匹林对比安慰剂试验提供低等级证据表明，两组间的血栓形成率没有区别。[51]Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382-2391.http://onlinelibrary.wiley.com/doi/10.1002/art.22663/fullhttp://www.ncbi.nlm.nih.gov/pubmed/17599766?tool=bestpractice.com
